China SXT Pharmaceuticals, Inc. (SXTC)
NASDAQ: SXTC · Real-Time Price · USD
1.420
-0.030 (-2.07%)
Oct 16, 2025, 4:00 PM EDT - Market closed
China SXT Pharmaceuticals Revenue
In the fiscal year ending March 31, 2025, China SXT Pharmaceuticals had annual revenue of $1.74M, down -9.73%. China SXT Pharmaceuticals had revenue of $911.42K in the half year ending March 31, 2025, with 19.39% growth.
Revenue (ttm)
$1.74M
Revenue Growth
-9.73%
P/S Ratio
1.16
Revenue / Employee
$23,212
Employees
75
Market Cap
164.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.74M | -187.59K | -9.73% |
| Mar 31, 2024 | 1.93M | -43.18K | -2.19% |
| Mar 31, 2023 | 1.97M | -630.60K | -24.23% |
| Mar 31, 2022 | 2.60M | -2.18M | -45.53% |
| Mar 31, 2021 | 4.78M | -384.70K | -7.45% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
SXTC News
- 7 months ago - China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency - GlobeNewsWire
- 8 months ago - China SXT Pharmaceuticals, Inc. Announces Share Consolidation - GlobeNewsWire
- 1 year ago - China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency - GlobeNewsWire
- 2 years ago - China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule - GlobeNewsWire
- 2 years ago - China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split - GlobeNewsWire
- 3 years ago - China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split - GlobeNewsWire
- 3 years ago - China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million - GlobeNewsWire
- 4 years ago - Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC). - Accesswire